Current Atherosclerosis Reports

Article	Citations
Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity	87
APOA1: a Protein with Multiple Therapeutic Functions	85
Food Insecurity and Cardiovascular Disease Risk	81
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease	74
COVID and Cardiovascular Disease: What We Know in 2021	71
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?	61
High-Density Lipoproteins and Serum Amyloid A (SAA)	58
Time-Restricted Eating to Improve Cardiovascular Health	52
Lipid Lowering Drugs: Present Status and Future Developments	48
Statins and Inflammation	45
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues	44
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets	44
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	44
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	38
Bempedoic Acid: for Whom and When	38
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	37
Phytosterols and Cardiovascular Disease	35
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?	34
Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat	32
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	31
Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis	28
Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States	28
HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis	27
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease	27
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics	26

High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis	26
Apolipoprotein E and Atherosclerosis	25
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors	25
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?	25
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease	24
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	24
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease	24
The Genetic Basis of Hypertriglyceridemia	23
Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents	23
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	22
RNA Silencing in the Management of Dyslipidemias	22
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	22
The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes	22
LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective	21
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases	21
Obesity and Dyslipidemia	21
The Role of High-Density Lipoprotein Cholesterol in 2022	21
Ambient Air Pollution and Atherosclerosis: Recent Updates	21
Lp(a): a New Pathway to Target?	20
Sex Differences in Coronary Atherosclerosis	20
A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke	20
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis	20
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice	20
Lipoprotein (a): When to Measure and How to Treat?	20
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis	20
Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes	19
Childhood Obesity and Cardiovascular Disease Risk	19
Lipid Phenotypes and DNA Methylation: a Review of the Literature	19
Inclisiran: How Widely and When Should We Use It?	19
The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis	18
MicroRNAs and Circular RNAs in Lipoprotein Metabolism	18
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?	18
Novel RNAi-Based Therapies for Atherosclerosis	17
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?	17
Obesity Management in Cardiometabolic Disease: State of the Art	17
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	17
Lipoprotein (a): Recent Updates on a Unique Lipoprotein	17
Contributions of Food Environments to Dietary Quality and Cardiovascular Disease Risk	17
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	17
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	16
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	16
Updates in Drug Treatment of Severe Hypertriglyceridemia	16
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism	16
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)	16
Hypertension in Women Across the Lifespan	16
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center	15
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health	15
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies	15
Free Cholesterol Bioavailability and Atherosclerosis	15
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk	14

Gene-Environment Interactions for Cardiovascular Disease	14
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	13
Novel Functions of Endothelial Scavenger Receptor Class B Type I	13
A Nutrigenetic Update on CETP Gene–Diet Interactions on Lipid-Related Outcomes	13
The Role of Calorie Restriction in the Prevention of Cardiovascular Disease	13
Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime	12
Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia	12
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	12
Coconut Oil and Cardiovascular Disease Risk	12
Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia	12
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?	12
Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?	12
Structure-based mechanism and inhibition of cholesteryl ester transfer protein	11
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	11
Takotsubo Syndrome: Uncovering Myths and Misconceptions	11
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	11
Sustainable Diets for Cardiovascular Disease Prevention and Management	11
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments	10
Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?	10
Behavioral Medicine for Sedentary Behavior, Daily Physical Activity, and Exercise to Prevent Cardiovascular Disease: A Review	10
Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia	10
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	10
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future	10
Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia	10
Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy	10
Update on Sitosterolemia and Atherosclerosis	10
Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?	9
Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination	9
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	9
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	9
Diabetes, Lipids, and CV Risk	9
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	9
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	9
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	9
Plant- and Animal-Based Protein-Rich Foods and Cardiovascular Health	9
Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation	9
Telomere Length: Implications for Atherogenesis	9
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	9
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	9
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	8
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	8
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	8
Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology	8
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology	8
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	8
Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins	8
Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease	8
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference	8
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	8
Update on Plant-Based Diets and Cardiometabolic Risk	8
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	8
Cardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention	8
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	7
mHealth Technology and CVD Risk Reduction	7
Transintestinal cholesterol excretion in health and disease	7
Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention	7
How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?	7
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	7
Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone?	7
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia	7
Lipoprotein(a): from Causality to Treatment	7
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	7
How to Handle Elevated Triglycerides: Life after PROMINENT	6
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome	6
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era	6
Strengthening the Learning Health System in Cardiovascular Disease Prevention: Time to Leverage Big Data and Digital Solutions	6
Nutrition as Treatment Modality in Heart Failure	6
Breast Arterial Calcification: A Potential Biomarker for Atherosclerotic Cardiovascular Disease Risk?	6
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions	6
Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions	6
Fixed Combination for the Treatment of Dyslipidaemia	6
Atherosclerosis in Systemic Lupus Erythematosus	6
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	6
Sex Differences in Familial Hypercholesterolemia	6
Community-Based Interventions to Address Disparities in Cardiometabolic Diseases Among Minoritized Racial and Ethnic Groups	6
Treatment of Lp(a): Is It the Future or Are We Ready Today?	6
How ANGPTL3 Inhibition Will Help Our Clinical Practice?	6
T-cell Cholesterol Accumulation, Aging, and Atherosclerosis	6
Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention	5
Bioactives in the Food Supply: Effects on CVD Health	5

Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	5
Clonal Hematopoiesis: Connecting Aging and Inflammation in Atherosclerosis	5
Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials	5
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	5
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	5
Importance of Nutrition Security to CVD Prevention Efforts in the USA	5
Imaging Approaches to the Diagnosis of Vascular Diseases	5
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions	5
Improving Maternal Cardiovascular Health in Underserved Populations: a Narrative Review of Behavioral Intervention Trials Targeting Postpartum Weight Retention	5
CETP Inhibitors: Should We Continue to Pursue This Pathway?	5
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	5
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	5
How to Mitigate Risk of Premature Cardiovascular Disease Among Children and Adolescents with Mental Health Conditions	5
COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave	5
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	4
Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management	4
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	4
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	4
The Pandemic of Coronary Artery Disease in the Sub-Saharan Africa: What Clinicians Need to Know	4
AIBP, Angiogenesis, Hematopoiesis, and Atherogenesis	4
Family Meals and Cardiometabolic Risk Factors in Young Children	4
Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors	4
Apheresis: What Should a Clinician Know?	4
Lipoprotein(a): a Case for Universal Screening in Youth	4
Utility of FFRCT in Patients with Chest Pain	4
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	4
Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment	4
Sex Differences in Cardiac Transplantation	4
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	4
Risk Factors for Cardiovascular Disease: Knowledge Gained from the Hispanic Community Health Study/Study of Latinos	4
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	4
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	4
Next Generation Risk Markers in Preventive Cardio-oncology	4
Coronary Artery Calcium for Risk Assessment in Young Adults	4
Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress	4